Monopar Therapeutics (NASDAQ:MNPR) Shares Up 0.4% - What's Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) shares rose 0.4% during mid-day trading on Wednesday . The stock traded as high as $36.55 and last traded at $34.65. Approximately 11,648 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 358,561 shares. The stock had previously closed at $34.51.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Piper Sandler reissued an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $55.33.

Monopar Therapeutics Price Performance

The firm's fifty day moving average is $36.98 and its two-hundred day moving average is $33.79. The firm has a market capitalization of $206.81 million, a PE ratio of -17.17 and a beta of 0.99.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27. As a group, equities research analysts predict that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the transaction, the insider now directly owns 822,255 shares in the company, valued at $28,778,925. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new stake in Monopar Therapeutics in the fourth quarter worth about $23,435,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at $13,182,000. RA Capital Management L.P. purchased a new position in shares of Monopar Therapeutics in the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. purchased a new stake in Monopar Therapeutics during the 4th quarter valued at about $3,694,000. Finally, ADAR1 Capital Management LLC bought a new stake in Monopar Therapeutics during the 4th quarter valued at about $2,861,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.